– USA, CA – ChemoCentryx, Inc. (Nasdaq:CCXI), announced today that, effective March 27, 2019, Rita Jain, M.D., Senior Vice President and Chief Medical Officer of Akebia Therapeutics, has been appointed to the Company’s Board of Directors.
Dr. Jain brings more than 20 years of drug development experience spanning academia and industry, with expertise across a range of therapeutic areas.
“Dr. Jain brings a wealth of experience in biotechnology and pharmaceutical development. She joins us at a pivotal point in our forward integration as we approach successive late-stage data readouts and plan for commercialization,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Dr. Jain’s experience leading multiple global programs across various stages of development will be an asset. Her leadership in the successful completion of AbbVie’s Phase II uterine fibroid program and the largest endometriosis Phase III program to date, which led to FDA approval for ORILISSA, is a testament to the value she brings to ChemoCentryx.”
About Dr Rita Jain
Dr. Jain currently serves as the Senior Vice President and Chief Medical Officer of Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease. Prior to joining Akebia in May 2017, Dr. Jain was Vice President of Men’s and Women’s Health and Metabolic Development at AbbVie, Inc. Before that, Dr. Jain held various positions including Divisional Vice President and Vice President in Pharmaceutical Development at Abbott Laboratories, and after AbbVie’s split from Abbott, at AbbVie. In addition to her work in men’s and women’s health, and metabolic development, Dr. Jain also led activities in pain, respiratory, and cystic fibrosis development. Before AbbVie, she held management positions in the Arthritis, Inflammation and Pain Group at Searle (acquired by Pharmacia and subsequently Pfizer). Prior to joining Searle, Dr. Jain was a faculty member at North Shore University Hospital in New York, with an academic appointment as Assistant Professor of Medicine, New York University School of Medicine.
“Much of my career has been dedicated to developing therapies to address unmet medical needs, so I look forward to supporting ChemoCentryx in its pursuit of differentiated small molecules aimed at not only halting disease, but also doing so without the toxic side-effects associated with current standard of care treatments,” said Dr. Jain. “ChemoCentryx has strong science, a broad pipeline and has made significant progress toward achieving its objectives. I’m excited to join the Board at such a transformational time and to contribute to the company’s continued growth.”
Dr. Jain received her B.S. in biology from LIU/C.W. Post and her M.D. from the State University of New York at Stony Brook School of Medicine. Dr. Jain completed her medical training in internal medicine at Staten Island University Hospital followed by a Fellowship in Rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.
ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx is currently focusing on its late stage drug candidates for patients with rare diseases, avacopan and CCX140.
Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR. Avacopan is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA-associated Vasculitis). In clinical studies to date, avacopan was shown to be safe, well tolerated and provided effective control of the disease while allowing elimination of high-dose steroids, part of the current standard of care. ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S. Food and Drug Administration has granted avacopan orphan-drug designation for ANCA-associated Vasculitis, C3G and atypical hemolytic uremic syndrome (aHUS). The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA-associated Vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener’s granulomatosis), as well as for C3G. Avacopan was also granted access to the European Medicines Agency’s PRIority MEdicines initiative, which supports accelerated assessment of investigational therapies addressing unmet medical need.
The Company’s other late stage drug candidate is CCX140, an inhibitor of the chemokine receptor known as CCR2, which is currently being developed for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease. The U.S. Food and Drug Administration has granted CCX140 orphan-drug designation for the treatment of FSGS.
ChemoCentryx’s Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan and CCX140 in markets outside of the U.S.
ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other Inflammatory and autoimmune diseases and in cancer.
For more information : http://www.chemocentryx.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.